[{"address1": "280 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 231 6625", "website": "https://www.alumis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 221, "companyOfficers": [{"maxAge": 1, "name": "Mr. Martin  Babler Ph.D.", "age": 59, "title": "President, CEO & Chairman", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 912638, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David M. Goldstein Ph.D.", "age": 58, "title": "Chief Scientific Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 651368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Roy C. Hardiman J.D.", "age": 64, "title": "Chief Business & Strategy Officer", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 619841, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John R. Schroer C.F.A.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sanam  Pangali J.D.", "title": "Chief Legal Officer & Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Claire  Langrish Ph.D.", "title": "Senior VP & Head of Immunology and Translational Science", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip  Nunn Ph.D.", "title": "Senior VP of Pharmacology & Project Team Leader", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jorn  Drappa M.D., Ph.D.", "age": 59, "title": "Chief Medical Officer & Head of Research and Development", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Bradley", "age": 59, "title": "Chief Development Officer", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kolbot  By Ph.D.", "title": "Senior VP & Head of Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 11.06, "open": 11.04, "dayLow": 10.994, "dayHigh": 11.365, "regularMarketPreviousClose": 11.06, "regularMarketOpen": 11.04, "regularMarketDayLow": 10.994, "regularMarketDayHigh": 11.365, "payoutRatio": 0.0, "forwardPE": -3.517134, "volume": 1363030, "regularMarketVolume": 1363030, "averageVolume": 954139, "averageVolume10days": 1529240, "averageDailyVolume10Day": 1529240, "bid": 8.23, "ask": 13.44, "bidSize": 2, "askSize": 2, "marketCap": 1178601472, "fiftyTwoWeekLow": 2.76, "fiftyTwoWeekHigh": 12.44, "allTimeHigh": 13.53, "allTimeLow": 2.76, "priceToSalesTrailing12Months": 53.279755, "fiftyDayAverage": 6.7061, "twoHundredDayAverage": 5.001525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 838674496, "profitMargins": 0.0, "floatShares": 59870661, "sharesOutstanding": 97208495, "sharesShort": 3533932, "sharesShortPriorMonth": 2812394, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.0339, "heldPercentInsiders": 0.00822, "heldPercentInstitutions": 0.81428003, "shortRatio": 3.35, "shortPercentOfFloat": 0.1188, "impliedSharesOutstanding": 104393403, "bookValue": 3.687, "priceToBook": 3.0621102, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -245152992, "trailingEps": -2.15, "forwardEps": -3.21, "enterpriseToRevenue": 37.913, "enterpriseToEbitda": -1.909, "52WeekChange": 0.32138586, "SandP52WeekChange": 0.1340276, "quoteType": "EQUITY", "currentPrice": 11.29, "targetHighPrice": 25.0, "targetLowPrice": 17.0, "targetMeanPrice": 19.85714, "targetMedianPrice": 20.0, "recommendationMean": 1.125, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 377724000, "totalCashPerShare": 3.618, "ebitda": -439332000, "totalDebt": 37797000, "quickRatio": 5.83, "currentRatio": 6.012, "totalRevenue": 22121000, "debtToEquity": 9.823, "revenuePerShare": 0.305, "returnOnAssets": -0.61458, "returnOnEquity": -0.66876, "grossProfits": 22121000, "freeCashflow": -190766128, "operatingCashflow": -372380000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -53.72314, "financialCurrency": "USD", "symbol": "ALMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "earningsTimestampStart": 1763154000, "earningsTimestampEnd": 1763154000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.15, "epsForward": -3.21, "epsCurrentYear": -2.88, "priceEpsCurrentYear": -3.9201388, "fiftyDayAverageChange": 4.5839, "fiftyDayAverageChangePercent": 0.68354183, "twoHundredDayAverageChange": 6.288475, "twoHundredDayAverageChangePercent": 1.2573116, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-06-28", "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "marketState": "CLOSED", "shortName": "Alumis Inc.", "longName": "Alumis Inc.", "corporateActions": [], "postMarketTime": 1766186373, "regularMarketTime": 1766178002, "exchange": "NMS", "messageBoardId": "finmb_705657695", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.07956, "regularMarketPrice": 11.29, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1719581400000, "postMarketChangePercent": 0.797167, "postMarketPrice": 11.38, "postMarketChange": 0.09000015, "regularMarketChange": 0.23, "regularMarketDayRange": "10.994 - 11.365", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 954139, "fiftyTwoWeekLowChange": 8.53, "fiftyTwoWeekLowChangePercent": 3.0905795, "fiftyTwoWeekRange": "2.76 - 12.44", "fiftyTwoWeekHighChange": -1.1499996, "fiftyTwoWeekHighChangePercent": -0.092443705, "fiftyTwoWeekChangePercent": 32.138588, "displayName": "Alumis", "trailingPegRatio": null, "__fetch_time": "2025-12-20"}]